This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Asensus Surgical (ASXC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -12.50% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Cardinal Health (CAH)
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.
Henry Schein (HSIC) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 4.80% and 0.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Cardinal (CAH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cardinal (CAH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Cardinal Health (CAH) to Build Distribution Center in Greenville
by Zacks Equity Research
Cardinal Health's (CAH) new facility will be its largest at-Home Solutions distribution center that will support business growth by providing new space and automation.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights McDonald's, W.W. Grainger and Cardinal Health
by Zacks Equity Research
McDonald's, W.W. Grainger and Cardinal Health are included in this Analyst Blog.
3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
3 Top S&P 500 Stocks to Buy as Index Tastes 4200 Mark
by Tirthankar Chakraborty
Banking on recent strengths, investors should place their bets on sound stocks like McDonald's (MCD), W.W. Grainger (GWW) & Cardinal Health (CAH) that are poised to scale upward along with the broader S&P 500 Index.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
by Zacks Equity Research
For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.
Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod
by Zacks Equity Research
Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.
Zacks.com featured highlights include Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International
by Zacks Equity Research
Cardinal Health, Boyd Gaming, Ford Motor, NXP Semiconductors N.V and American International are part of the Zacks Screen of the Week article.
Abbott's (ABT) New Pact to Advance Clinical Trials Diversity
by Zacks Equity Research
Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.
Here's Why You Should Retain Veeva Systems (VEEV) Stock Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Here's Why You Should Retain Veradigm (MDRX) Stock for Now
by Zacks Equity Research
Veradigm (MDRX) continues to hold on to investors' interests owing to its strategic alliances.
5 Attractive Value Picks Based on Discounted PEG
by Urmimala Biswas
Here are five stocks that meet our screening criteria - CAH, BYD, F, NXPI, AIG.
National Vision (EYE) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.